en · de · es · fr · pt
thymosin-alpha-1-notes.peptides5388.com › Guide › Identity And Molecular Background — Explained

Identity And Molecular Background — Explained

By Editorial Desk · published 2025-08-12 · last reviewed 2025-09-29 · Guide

If you have been reading about 免疫调节 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2025-09-29. Numbers and descriptions here follow the published literature rather than marketing material.

Identity and Molecular Background

The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.

Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.

Molecular Background and Identity

Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.

Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.

Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.

Thymosin-alpha-1 at a glance

PropertyValueNotes
Molecular formulaC129H215N33O55Calculated for the acetylated 28-residue peptide
AppearanceWhite to off-white powderLyophilized solid recovered from aqueous buffer
SolubilityFreely soluble in waterTypically dissolved in water or buffer before use
Typical storage-20 C or below, desiccatedProtect from light and avoid repeated freeze-thaw cycles
Identity testingReverse-phase HPLC with mass spectrometryRetention time and measured mass confirm the sequence

Storage Stability and Analytical Testing

Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.

Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.

Related pages on this site

Handling, Storage, and Analytical Verification

Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.

Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.

免疫调节机制与信号

胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明,它可促进未成熟T细胞向成熟T细胞分化,并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子,从而更有效地呈递抗原。此外,自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体,而是调节宿主免疫应答的强度与方向。

在信号层面,Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示,它能激活髓样分化因子88依赖的通路,进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答,有助于细胞免疫。然而,具体受体和结合位点尚未完全确定,不同实验模型的结果存在差异。

临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善,但临床终点获益在不同研究中并不一致。系统综述指出,研究间在人群、剂量和联合方案上差异较大,难以汇总结论。因此,Tα1的确切临床地位仍属开放问题,需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。

Notes from published material

== Taxonomy == Hybridization studies from 1995 indicate that species within the genus Micrococcus are not closely related, showing as little as 50% sequence similarity. This suggests that some Micrococcus species may, on the basis of ribosomal RNA analysis, eventually be re-classified into other microbial genera.

There was no difference in outcome between the groups and the authors concluded that, whatever the benefits of the coma regimen, insulin was not the specific therapeutic agent. In 1958, American neuropsychiatrist Max Fink published in the Journal of the American Medical Association the results of a random controlled comparison in 60 patients treated with 50 iatrogenic insulin-induced comas or chlorpromazine in doses from 300 mg to 2000 mg/day. The results were essentially the same in relief and discharge ratings but chlorpromazine was safer with fewer side-effects, easier to administer, and better suited to long-term care. In 1958, Bourne published a paper on increasing disillusionment in the psychiatric literature about insulin coma therapy for schizophrenia. He suggested there were several reasons it had received almost universal uncritical acceptance by reviews and textbooks for several decades despite the occasional disquieting negative finding, including that, by the 1930s when it all started, schizophrenics were considered inherently unable to engage in psychotherapy, and insulin coma therapy "provided a personal approach to the schizophrenic, suitably disguised as a physical treatment so as to slip past the prejudices of the age." By the 1970s, insulin shock therapy had mostly fallen out of use in the United States, though was still practiced in some hospitals. Its use may have continued longer in China, India, and the Soviet Union.

The genetic and nongenetic targets of the receptors differ between homo and heterodimers. Ligation of these receptors allows them to translocate to the nucleus and act as transcription factors either by binding estrogen response elements (ERE) on DNA or binding DNA together with other transcriptional factors e.g. Nf-kB or AP-1, both of which result in RNA polymerase recruitment and further chromatin remodelation. A non-transcriptional response to oestrogen stimulation was also documented (termed membrane-initiated steroid signalling, MISS). This pathway stimulates the ERK and PI3K/AKT pathways, which are known to increase cellular proliferation and affect chromatin remodelation.

pre-formulation, formulation development, stability studies, method development, pre-clinical and Phase I clinical trial materials, late-stage clinical trial materials, formal stability, scale-up, registration batches and commercial production. CDMOs are contract manufacturers, yet they provide development as a standard part of their services. Their customers are not only expecting competitive pricing, but also regulatory compliance, flexibility on the production capability and on-time delivery. Overall it is required that CMO complies with good manufacturing practice from their client and regulatory bodies such as the Food and Drug Administration.

Sources: en.wikipedia.org

Background from the literature

After they finished, Sean Kinney looked at his bandmates and said, "I think the search is pretty much over." According to Mike Inez, DuVall didn't try to emulate Staley, and that's what drew them to him. Cantrell revealed that before he suggested DuVall for the band, Sean Kinney and Mike Inez invited Sponge and Spys4Darwin lead vocalist Vin Dombroski to jam with the band in their rehearsal space. Dombroski jammed with them to a couple of songs but they did not feel he was right for the band. According to Cantrell, Stone Temple Pilots and Velvet Revolver lead singer Scott Weiland was also interested in joining the band.

== Traffic tunnels == Traffic tunnels may be traversed by vehicles carrying flammable goods, such as petrol, liquefied petroleum gas and other hydrocarbons, which are known to cause a very rapid temperature rise and high ultimate temperatures in case of a fire (see the hydrocarbon curves in fire-resistance rating). Where hydrocarbon transports are permitted in tunnel construction and operations, accidental fires may occur, resulting in the need for fireproofing of traffic tunnels with concrete linings.

Insulin coma therapy was a labour-intensive treatment that required trained staff and a special unit. Patients, who were almost invariably diagnosed with schizophrenia, were selected on the basis of having a good prognosis and the physical strength to withstand an arduous treatment. There were no standard guidelines for treatment. Different hospitals and psychiatrists developed their own protocols. Typically, injections were administered six days a week for about two months. The daily insulin dose was gradually increased to 100–150 units (1 unit = 34.7 μg) until comas were produced, at which point the dose would be levelled out. Occasionally, doses of up to 450 units were used. After about 50 or 60 comas, or earlier if the psychiatrist thought that maximum benefit had been achieved, the dose of insulin was rapidly reduced before treatment was stopped. Courses of up to 2 years have been documented. After the insulin injection patients would experience various symptoms of decreased blood glucose: flushing, pallor, perspiration, salivation, drowsiness or restlessness. Sopor and coma—if the dose was high enough—would follow. Each coma would last for up to an hour and be terminated by intravenous glucose or via naso-gastric tube. Seizures occurred before or during the coma. Many would be tossing, rolling, moaning, twitching, spasming or thrashing around.

Sources: en.wikipedia.org

Frequently asked questions

What is thymosin alpha 1?

It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.

Is thymosin alpha 1 the same as thymosin beta 4?

No. The two peptides share part of a name but differ in length, sequence, and net charge. Literature searches that treat them as one compound return misleading results.

How is the peptide obtained for laboratory work?

Solid-phase peptide synthesis is the usual route, and recombinant expression has also been described. Both approaches produce material matching the natural sequence.

Is thymosin alpha 1 a hormone?

The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.

Network